Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03351244 · ClinicalTrials.gov registry record · Phase 2
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
NCT03351244 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 264 participants.
The verdict
NCT03351244, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
Study Summary
The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.
Interventions
- DRUG Placebo
- DRUG BI 409306
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03351244
The ClinicalTrials.gov registry entry for NCT03351244 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03351244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03351244 about?
NCT03351244 is a clinical study titled "This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months". The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of ...
What is the current status of trial NCT03351244?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2017-12-07. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03351244?
The interventions under investigation include: Placebo (DRUG), BI 409306 (DRUG).
Who is sponsoring clinical trial NCT03351244?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.